Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma
First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the PATHFINDER